Analysis of Liver Fibrosis Degree with APRI Score and FIB-4 Index on Patients with Non-Alcoholic Fatty Liver Disease

Gillian Elvira Seipalla, Nurahmi Nurahmi, Ibrahim Abd Samad


Liver fibrosis is the accumulation of Extracellular Matrix Protein (EMP) scar tissue after acute or chronic liver injury. Liver
biopsy is the gold standard test for evaluating liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). This
diagnostic method is invasive, painful, and complicated in rare cases; thus the noninvasive methods such as laboratory tests
and radiology had been proposed to assess liver fibrosis in NAFLD and are expected to overcome the limitations of liver
biopsy. This method consists of aspartate Aminotransferase to the Platelet Ratio Index (APRI) and fibrosis-4 (FIB-4).This
research was retrospective cross-sectional performed at Dr. Wahidin Sudirohusodo Hospital Makassar involving 63 subjects
from January to June 2018. The correlated variables were presented in categorical and numerical data and the Pearson
correlation test was used to determine the compatibility of APRI score and FIB-4 index with Fibroscan result in patients
with NAFLD. A highly significant positive correlation (p <0.001) was found between APRI score and Fibroscan (correlation
value = 45.8%), APRI score and FIB-4 index (correlation value = 91.8%), FIB-4 index and Fibroscan (correlation
value = 47.6%). The score of Aminotransferase to platelet ratio index score and FIB-4 index could be an alternative method
instead of a liver biopsy to predict the degree of fibrosis in patients with NAFLD.


Liver fibrosis, APRI score, FIB-4 index

Full Text:



Ahmet Aslan, et al. Effect of Nonalcoholic Fatty Liver Disease on the Hepatic Vein and Artery. Research Article; 2014.p 1-4

Kareem Hassan, et al. Nonalcoholic Fatty Liver Disease: A Comprehensiv Review of a Growing Epidemic. World Journal of Gastroenterology; 2014. p.12082-101

Elena Buzzetti, Rosa L et al. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology, Vol.XII; 2015. p 1-4.

Linda Ferrel. Update on Staging of Fibrosis and Cirrhosis. University of California ;2013. p.1-22.

Hind I. Fallatah, Noninvasive Biomarkers of Liver Fibrosis, Advance in Hepatology; 2014. p 1-15.

Thad Wilkins, Altaf Tadkod et al, Nonalcoholic Fatty Liver Disease: Diagnosis and Management. American Family Physician, 2013.p. 35-42.

Surastik Agrawal and Ajay K Duseja. Non-Alcoholic Fatty Liver Disease: East Versus West. Journal of Ccinical and Experimental.Hepatology; 2012 Vol 2. p.122-134.

Mustakin. Analisis Derajat Fibrosis Hati dengan Fibroscan, FIB4 Indeks, King Score, dan APRI Score pada pasien penyakit hepatitis kronis. Departemen Ilmu Patologi Klinik. Universitas Hassanudin. 2015.

Atsushi Nakajima, Yoshio S et al. Non-invasive scoring systems for predicting NASH in Japan: evidence from Japan Study Group of NAFLD, Integrative Molecular Medicine; 2015. p.145-149.

Becker L, Evaluation and Staging of Liver Fibrosis; 2015. p. 1-16.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.